NexImmune, a start-up company formed in part by US-based Johns Hopkins University School of Medicine faculty members, has hired both a executive president and a chairman of its clinical and scientific advisory board as part of a technology transfer license for developing immunity against diseases and cancers.
Kenneth Carter has joined NexImmune as its executive president and Jonathan Schneck has become chairman of the company’s Clinical and Scientific Advisory Board.
Previously, Carter was also chief executive for 10 years at Avalon Pharmaceuticals until its merger with Clinical Data.
Prior to Avalon, Carter directed the gene mapping initiative at Human Genome Sciences, which discovered, cloned, and chromosomal mapped dozens of novel human genes and he is also on the advisory council for the Center for Biotechnology Education at The Johns Hopkins University, where he also holds an adjunct faculty appointment.
Schneck is a professor of pathology, oncology and medicine and…
